Biosimilar
Improving Accessibility and Affordability of Existing Biological Drugs
Prestige Biopharma believes in the potential of biosimilars and the contribution they make towards establishing a sustainable future for biologic medicines. Our goal is to enhance patient treatment accessibility by offering biological medicines that are affordable, safe, and of high quality. Our portfolio consists of 12 biosimilars, including, HD201 (trastuzumab biosimilar) currently under regulatory review, HD204 (bevacizumab biosimilar) in Phase 3 clinical study and PBP1502 (adalimumab biosimilar) in Phase 1 clinical study.
Our groundbreaking accomplishments
Pipeline
INN
Therapeutic Area
Development Stage
Herceptin®
Trastuzumab
Oncology
Filing (EU)
Avastin®
Bevacizumab
Oncology
Clinical (Phase 3)
Humira®
Adalimumab
Immunology
Clinical (Phase 1)
Prolia®
Denosumab
Endocrinology
Preclinical
Eylea®
Aflibercept
Ophthalmology
Preclinical
Opdivo®
Nivolumab
Oncology
Discovery
Keytruda®
Pembrolizumab
Oncology
Discovery
Soliris®
Eculizumab
Immunology
Discovery
Yervoy®
Ipilimumab
Oncology
Discovery
Perjeta®
Pertuzumab
Oncology
Discovery
Hemlibra®
Emicizumab
Hematology
Discovery
Stelara®
Ustekinumab
Immunology
Discovery
Trulicity®
Dulaglutide
Endocrinology
Discovery
Ocrevus®
Ocrelizumab
Immunology
Discovery
Vedolizumab
Immunology
Discovery
Herceptin®
INN | Therapeutic Area | Development Stage |
Trastuzumab | Oncology | Filing (EU) |
Avastin®
INN | Therapeutic Area | Development Stage |
Bevacizumab | Oncology | Clinical (Phase 3) |
Humira®
INN | Therapeutic Area | Development Stage |
Adalimumab | Immunology | Clinical (Phase 1) |
Prolia®
INN | Therapeutic Area | Development Stage |
Denosumab | Endocrinology | Preclinical |
Eylea®
INN | Therapeutic Area | Development Stage |
Aflibercept | Ophthalmology | Preclinical |
Opdivo®
INN | Therapeutic Area | Development Stage |
Nivolumab | Oncology | Discovery |
Keytruda®
INN | Therapeutic Area | Development Stage |
Pembrolizumab | Oncology | Discovery |
Soliris®
INN | Therapeutic Area | Development Stage |
Eculizumab | Immunology | Discovery |
Yervoy®
INN | Therapeutic Area | Development Stage |
Ipilimumab | Oncology | Discovery |
Perjeta®
INN | Therapeutic Area | Development Stage |
Pertuzumab | Oncology | Discovery |
Hemlibra®
INN | Therapeutic Area | Development Stage |
Emicizumab | Hematology | Discovery |
Stelara®
INN | Therapeutic Area | Development Stage |
Ustekinumab | Immunology | Discovery |
Trulicity®
INN | Therapeutic Area | Development Stage |
Dulaglutide | Endocrinology | Discovery |
Ocrevus®
INN | Therapeutic Area | Development Stage |
Ocrelizumab | Immunology | Discovery |
엔티비오®
INN | Therapeutic Area | Development Stage |
Vedolizumab | Immunology | Discovery |